06
Fri, Dec

world malaria day

  • ASAAP leads the way in assessing the viability of a triple therapy antimalarial via a multicenter clinical trial. Triple therapy is expected to significantly slow down the rate at which resistance of malaria parasites to medication develops.

    Seven reputable institutions across Sub-Saharan Africa, Germany, and France have come together to run the project ASAAP - Clinical evaluation of ArteSunate+Amodiaquine+Atovaquone-Proguanil tri-therapy for malaria treatment in African children. ASAAP is a 48-month-long multicenter clinical trial, coordinated by the Kumasi Center for Collaborative Research in Tropical Medicine (KCCR).

  • The workers will be trained to use larviciding, an insecticide that is specifically targeted at the larval life stage of an insect, particularly the mosquito, as part of the National Malaria Control Programme .

    A nationwide training programme to equip more than 10,000 personnel in the health sector to combat malaria has began.

Sign up via our free email subscription service to receive notifications when new information is available.